ReviewCurrent pharmaceutical design2025
Revisiting the Role of Long Non-coding RNA PSMA3-AS1 in Human Cancers: Current Evidence and Future Directions.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) refer to RNA molecules that exceed 200 nucleotides in length. While lncRNAs do not possess the capacity to encode proteins, they play crucial roles in gene expression, chromatin remodeling, and protein relocation. PSMA3 antisense RNA 1 (PSMA3-AS1) is a newly discovered lncRNA located on human chromosome 14q23.1. Convincing evidence shows that it acts as a tumor-promoting factor in several forms of human cancers. Moreover, high expression of PSMA3-AS1 is linked to poor clinical and pathological features and adverse prognosis in eight types of cancer. The molecular mechanisms of PSMA3- AS1 are diverse and complex. Existing evidence demonstrates that PSMA3-AS1 is activated by two transcription factors, PAX5 and YY-1, and influences cancer cell growth, metastasis, apoptosis, drug resistance, oxidative stress, and autophagy by acting as a competing endogenous RNA, activating signaling pathways, directly interacting with RNA or proteins, as well as participating in the epithelial-mesenchymal transition process. Therefore, PSMA3-AS1 holds promise as a biomarker for cancer detection and prediction, as well as a novel therapeutic target. This review explores the expression features, biological roles, potential mechanisms, and clinical significance of PSMA3-AS1 in various human cancers and provides directions for future research.
Indexed as
Identifiers
39901687What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.